These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

429 related items for PubMed ID: 30312438

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA.
    Drugs; 2019 Feb; 79(3):303-313. PubMed ID: 30689194
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T, Muto S, Miyake M, Tanaka T, Wang W.
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [Abstract] [Full Text] [Related]

  • 26. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease.
    Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S.
    BMC Nephrol; 2022 Oct 18; 23(1):334. PubMed ID: 36258169
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S, Muto S, Kawano H, Okada T, Shibasaki Y, Nakajima K, Ibuki T.
    Clin Exp Nephrol; 2021 May 18; 25(5):467-478. PubMed ID: 33471240
    [Abstract] [Full Text] [Related]

  • 31. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O, REPRISE Trial Investigators.
    N Engl J Med; 2017 Nov 16; 377(20):1930-1942. PubMed ID: 29105594
    [Abstract] [Full Text] [Related]

  • 32. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention.
    Côté G, Asselin-Thompstone L, Mac-Way F, René de Cotret P, Lacroix C, Desmeules S, Agharazii M.
    Int Urol Nephrol; 2020 Feb 16; 52(2):343-349. PubMed ID: 32008201
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature.
    Capuano I, Buonanno P, Riccio E, Rizzo M, Pisani A.
    Clin Nephrol; 2022 Mar 16; 97(3):131-140. PubMed ID: 34846296
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The effect of trichlormethiazide in autosomal dominant polycystic kidney disease patients receiving tolvaptan: a randomized crossover controlled trial.
    Uchiyama K, Kitayama C, Yanai A, Ishibashi Y.
    Sci Rep; 2021 Sep 03; 11(1):17666. PubMed ID: 34480075
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.
    Nowak KL, Moretti F, Bussola N, Steele CN, Gregory AV, Kline TL, Ramanathan S, Trapletti G, Furlanello C, McCormick L, Chonchol M.
    Am J Kidney Dis; 2024 Sep 03; 84(3):275-285.e1. PubMed ID: 38608748
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.